Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 252 participants.
Also called NCT06826872
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 252 participants
- Registry
-
NCT06826872
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06826872. Randomized; double masking; primary purpose treatment. Start 2024-06-12 (actual); primary completion 2025-10-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
- Condition
- Hypertension, Essential
- Condition
- Cardiovascular Diseases
- Condition
- Cardiology
- Intervention (Drug)
- SPC 1001 Mid2
- Intervention (Drug)
- SPC 2002
- Intervention (Drug)
- SPC 2003
- Intervention (Drug)
- SPC 2004
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Record details
- Record id
cardio:ct-nct06826872- Content hash
cc09b74a60709c5d827c37e6032d227619bbdd0c8ffc1e1bc8188da14d2b2972